US 11845808
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted A61KA61K38/00
Quick answer
US patent 11845808 (Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases) held by Protagonist Therapeutics, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K38/00